139 results on '"Pfeffer, Marc"'
Search Results
2. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
3. Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016
4. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure
5. Geographic Differences in Patients With Acute Myocardial Infarction in The PARADISE‐MI Trial
6. Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial
7. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
8. Health‐related quality of life outcomes in PARAGON‐HF
9. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
10. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
11. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial
12. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
13. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with HFpEF in the PARAGON‐HF trial
14. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
15. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
16. Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF
17. Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
18. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial
19. Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT
20. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics
21. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial
22. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
23. Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF
24. Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT
25. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure
26. Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction
27. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
28. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
29. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality
30. Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial
31. Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non‐sudden cardiac death in myocardial infarction survivors with heart failure
32. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
33. Klotho, fibroblast growth factor‐23, and the renin–angiotensin system — an analysis from the PEACE trial
34. The frailty syndrome and outcomes in the TOPCAT trial
35. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure
36. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial
37. Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction
38. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study
39. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality
40. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment
41. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction
42. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment
43. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme
44. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
45. On the restricted mean survival time curve in survival analysis
46. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
47. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme
48. Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved’ [Eur J Heart Fail2014;16:33-40]
49. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT
50. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.